Investigation Launched into Vistagen Therapeutics for Securities Fraud Claims with Upcoming Deadline

Investigation into Vistagen Therapeutics for Securities Fraud Claims

Faruqi & Faruqi, LLP, a renowned national law firm specializing in securities, has announced its inquiry into Vistagen Therapeutics, Inc. (NASDAQ: VTGN). This investigation arises from allegations of potential misconduct that could have significant repercussions for the company and its investors.

Background of the Investigation

The legal concerns pertain to claims that Vistagen and its executives may have violated federal securities laws. Reports suggest that the firm issued misleading statements and omitted critical adverse information about its Phase 3 trial results for fasedienol, a candidate aimed at treating social anxiety disorder. These developments have raised considerable alarm among investors.

On December 17, 2025, Vistagen revealed that its PALISADE-3 Public Speaking Challenge Study did not meet its primary efficacy endpoint. This announcement indicated that there was no statistically significant improvement in anxiety reduction compared to a placebo. The fallout from this news was immediate and severe; Vistagen’s stock plummeted by 80% in a single day, closing at just $0.86.

Call to Action for Investors

As the situation unfolds, potential plaintiffs are reminded of the upcoming March 16, 2026 deadline to apply as lead plaintiffs in a federal securities class action against Vistagen. The lead plaintiff plays a crucial role, representing the larger class of affected investors and guiding the litigation process.

Investors who acquired Vistagen securities between April 1, 2024, and December 16, 2025, are particularly urged to assess their legal options. According to James (Josh) Wilson, senior partner at Faruqi & Faruqi, anyone with losses from these transactions should reach out for a consultation to explore their rights and potential recovery avenues.

This legal action serves as a critical reminder for investors about the importance of vigilance in monitoring the companies they invest in, particularly regarding accuracy and transparency in corporate communications.

Whistleblower and Additional Information

Faruqi & Faruqi encourages not just impacted investors, but also whistleblowers, former employees, and shareholders who may have pertinent information about Vistagen’s operations and disclosures, to come forward. Sharing insights or experiences can significantly support the ongoing investigation.

For individuals seeking more information about the class action lawsuit against Vistagen Therapeutics, detailed resources and contact information have been made available on the Faruqi & Faruqi website, where investors can stay updated on developments.

In the fast-paced world of investment and corporate governance, understanding the implications of such legal matters is essential. As this case progresses, it highlights the need for accountability and transparent practices in publicly traded companies.

Conclusion

For Vistagen investors facing significant losses, the impending deadline for the lead plaintiff application offers a chance to assert their rights and potentially recover damages. This case underlines the ongoing risks associated with investing in stocks based on clinical and market forecasts. The next steps will be critical as the lawsuit evolves and more information comes to light.